Current priorities in clinical renal transplantation include increasing the rate of organ retrieval, expanding the therapeutic window of agents used for induction and maintenance immunosuppressive therapy, and mitigating the obliterative vasculopathy traditionally called chronic rejection. The primary focus of this review will be the currently expansive effort to develop safer and more effective therapies for the prevention and treatment of acute renal allograft rejection.
展开▼